Literature DB >> 29745882

The adenosinergic system: a potential player in the pathogenesis of ANCA-associated vasculitis?

Lovis Kling1, Bernhard K Krämer1, Benito A Yard1, Anna-Isabelle Kälsch2.   

Abstract

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a potentially lethal autoimmune disease whose pathology comprises disturbed T cell differentiation and functionality accompanied by dysfunctional autoreactive immunoglobulin development, culminating in destructive innate immune response as well. Purines, adenine nucleotides and adenosine in particular, have been elucidated as potent extracellular mediators for fine adjustment of these pivotal processes establishing human immunity. Therefore, the extracellular purinergic microenvironment is under control of ectonucleotidases CD39 and CD73 degrading pro-inflammatory adenosine triphosphate (ATP) to anti-inflammatory adenosine as well as adenosine deaminase bound to CD26 deactivating adenosine. Accordingly, the ATP P2X7 receptor was elicited to be responsible for promotion of inflammation, while predominantly the adenosine A2A receptor demonstrated the opposite. Recent reports pointed at the adenosinergic system to be crucially involved in AAV pathogenesis. Here, experimental evidence on ecto-enzymes controlling extracellular adenine nucleotide concentrations and purinergic signaling in the immune system with respect to its contribution to the AAV pathomechanism is reviewed besides unsolved problems being identified that require further investigation in order to develop new treatment strategies for AAV.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29745882

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  1 in total

1.  Characterization of the N6-etheno-bridge method to assess extracellular metabolism of adenine nucleotides: detection of a possible role for purine nucleoside phosphorylase in adenosine metabolism.

Authors:  Edwin K Jackson; Delbert G Gillespie; Dongmei Cheng; Zaichuan Mi; Elizabeth V Menshikova
Journal:  Purinergic Signal       Date:  2020-05-04       Impact factor: 3.765

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.